COVID-19 and neurology perspective

Shivani Singh; Ashok Kumar Ahirwar; Priyanka Asia; Niranjan Gopal; Kirti Kaim; Pradeep Ahirwar

doi:10.1515/hmbci-2020-0069

Article

COVID-19 and neurology perspective

Shivani Singh , Ashok Kumar Ahirwar , Priyanka Asia , Niranjan Gopal , Kirti Kaim and Pradeep Ahirwar

Published/Copyright: February 23, 2021

Published by

Become an author with De Gruyter Brill

Submit Manuscript Author Information Explore this Subject

From the journal Hormone Molecular Biology and Clinical Investigation Volume 42 Issue 1

Abstract

COVID-19 caused by SARS CoV2 (The novel corona virus) has already taken lives of many people across the globe even more than anyone could have imagined. This outbreak occurred in China and since then it is expanding its devastating effects by leaps and bounds. Initially it appeared to be an outbreak of pneumonia but soon it was found to be much more than that and the infectivity was found to be very high. This is the reason that it has taken whole globe in its trap and become a pandemic in such a short span of time. Death is occurring because it is a new virus and human body has no specific antibodies for it. Presently there is no approved vaccine so everyone is susceptible but people with co-morbidities appear to be in more risk and the best way for protection is social distancing and increasing one’s natural immunity by taking healthy diet and exercise. When a person is infected the clinical presentation ranges from asymptomatic to severe ARDS, sudden onset of anosmia, headache, cough may be the initial symptoms. This review is focused on immunopathology and effect of COVID-19 on neurological disorders and also the neurological manifestations and the treatment.

Keywords: COVID-19; neurology; neuropathology; SARS-CoV-2

Corresponding author: Dr. Ashok Kumar Ahirwar, MD, Assistant Professor, Department of Biochemistry, All India Institute of Medical Sciences, Nagpur, Maharashtra, 441108, India, Phone: +919654210832, E-mail: drashoklhmc@gmail.com

Acknowledgements

We are thankful to Dr. Satyendra Chandra Tripathi, Assistant Professor, Department of Biochemistry, All India Institute of Medical Sciences, Nagpur, Maharashtra, 441108, India.

Research funding: None declared.
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
Competing interests: Authors state no conflict of interest.
Informed consent: Not applicable.
Ethical approval: Not applicable.

References

1. Rothan, HA, Byrareddy, SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 2020:102433. https://doi.org/10.1016/j.jaut.2020.102433.Search in Google Scholar

2. Sohrabi, C, Alsafi, Z, O’Neill, N, Khan, M, Kerwan, A, Al-Jabir, A, et al.. World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19). Int J Surg 2020;76:71–6.10.1016/j.ijsu.2020.02.034Search in Google Scholar PubMed PubMed Central

3. Jin, Y, Yang, H, Ji, W, Wu, W, Chen, S, Zhang, W, et al.. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses 2020;12:372. https://doi.org/10.3390/v12040372.Search in Google Scholar

4. Shereen, MA, Khan, S, Kazmi, A, Bashir, N, Siddique, R. COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. J Adv Res 2020;24:91–8.10.1016/j.jare.2020.03.005Search in Google Scholar PubMed PubMed Central

5. Wan, Y, Shang, J, Graham, R, Baric, RS, Li, F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol 2020;94. https://doi.org/10.1128/JVI.00127-20.Search in Google Scholar

6. Lechien, JR, Chiesa-Estomba, CM, De Siati, DR, Horoi, M, Le Bon, SD, Rodriguez, A, et al.. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Oto-Rhino-Laryngol 2020;277:1.10.1007/s00405-020-05965-1Search in Google Scholar PubMed PubMed Central

7. Cascella, M, Rajnik, M, Cuomo, A, Dulebohn, SC, Di Napoli, R. Features, evaluation and treatment coronavirus (COVID-19). Treasure Island: StatPearls Publishing.Search in Google Scholar

8. Klok, FA, Kruip, MJ, Van der Meer, NJ, Arbous, MS, Gommers, DA, Kant, KM, et al.. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020;191:145–7.10.1016/j.thromres.2020.04.013Search in Google Scholar PubMed PubMed Central

9. Long, B, Brady, WJ, Koyfman, A, Gottlieb, M. Cardiovascular complications in COVID-19. Am J Emerg Med 2020;38:1504–7. https://doi.org/10.1016/j.ajem.2020.03.049.Search in Google Scholar

10. Filatov, A, Sharma, P, Hindi, F, Espinosa, PS. Neurological complications of coronavirus disease (COVID-19): encephalopathy. Cureus 2020;12.10.7759/cureus.7352Search in Google Scholar PubMed PubMed Central

11. Carod-Artal, FJ. Neurological complications of coronavirus and COVID-19. Rev Neurol 2020;70:311–22. https://doi.org/10.33588/rn.7009.2020179.Search in Google Scholar

12. Singhal, T. A review of coronavirus disease-2019 (COVID-19). Indian J Pediatr 2020;87:1–6.10.1007/s12098-020-03263-6Search in Google Scholar

13. Zhou, M, Zhang, X, Qu, J. Coronavirus disease 2019 (COVID-19): a clinical update. Front Med 2020;14:126–35.10.1007/s11684-020-0767-8Search in Google Scholar

14. Steardo, L, SteardoJrL, Zorec, R, Verkhratsky, A. Neuroinfection may contribute to pathophysiology and clinical manifestations of COVID‐19. Acta Physiol 2020:e13473.10.1111/apha.13473Search in Google Scholar

15. Felsenstein, S, Herbert, JA, McNamara, PS, Hedrich, CM. COVID-19: immunology and treatment options. Clin Immunol 2020;215:108448. https://doi.org/10.1016/j.clim.2020.108448.Search in Google Scholar

16. van de Veerdonk, F, Netea, MG, van Deuren, M, van der Meer, JW, de Mast, Q, Bruggemann, RJ, et al.. Kinins and cytokines in COVID-19: a comprehensive pathophysiological approach. Preprints, 2020. https://doi.org/10.20944/preprints202004.0023.v1.10.20944/preprints202004.0023.v1Search in Google Scholar

17. McGonagle, D, Sharif, K, O’Regan, A, Bridgewood, C. Interleukin-6 use in COVID-19 pneumonia related macrophage activation syndrome. Autoimmun Rev 2020;19:102537. https://doi.org/10.1016/j.autrev.2020.102537.Search in Google Scholar

18. Mehta, P, McAuley, DF, Brown, M, Sanchez, E, Tattersall, RS, Manson, JJ, et al.. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet (London, England) 2020;395:1033. https://doi.org/10.1016/s0140-6736(20)30628-0.Search in Google Scholar

19. Troyer, EA, Kohn, JN, Hong, S. Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms. Brain Behav Immun 2020;87:34–9.10.1016/j.bbi.2020.04.027Search in Google Scholar PubMed PubMed Central

20. Conde, G, Pájaro, LD, Marzola, ID, Villegas, YR, Salazar, LR. Neurotropism of SARS-CoV 2: mechanisms and manifestations. J Neurol Sci 2020;15:412.10.1016/j.jns.2020.116824Search in Google Scholar

21. Prasanna, PL, Abilash, VG. Coronaviruses pathogenesis, comorbidities and multi-organ damage—A review. Life Sci 2020;255:117839.10.1016/j.lfs.2020.117839Search in Google Scholar PubMed PubMed Central

22. Henderson, LA, Canna, SW, Schulert, GS, Volpi, S, Lee, PY, Kernan, KF, et al.. On the alert for cytokine storm: immunopathology in COVID‐19. Arthritis Rheumatol 2020;72:1059–63.10.1002/art.41285Search in Google Scholar PubMed PubMed Central

23. Zhang, C, Wu, Z, Li, JW, Zhao, H, Wang, GQ. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents 2020:105954. https://doi.org/10.1016/j.ijantimicag.2020.105954.Search in Google Scholar

24. Papa, SM, Brundin, P, Fung, VS, Kang, UJ, Burn, DJ, Colosimo, C, et al.. MDS-Scientific Issues Committee. Impact of the COVID-19 pandemic on Parkinson’s disease and movement disorders. Mov Disord 2020;6.10.1002/mds.28067Search in Google Scholar PubMed PubMed Central

25. Singh, AK, Bhushan, B, Maurya, A, Mishra, G, Singh, SK, Awasthi, R. Novel Coronavirus disease 2019 (COVID‐19) and neurodegenerative disorders. Dermatol Ther 2020:e13591.10.1111/dth.13591Search in Google Scholar PubMed PubMed Central

26. Gutiérrez-Ortiz, C, Méndez, A, Rodrigo-Rey, S, San Pedro-Murillo, E, Bermejo-Guerrero, L, Gordo-Mañas, R, et al.. Miller Fisher Syndrome and polyneuritis cranialis in COVID-19. Neurology 2020;95:e601-5.10.1212/WNL.0000000000009619Search in Google Scholar PubMed

27. Sedaghat, Z, Karimi, N. Guillain Barre syndrome associated with COVID-19 infection: a case report. J Clin Neurosci 2020.10.1016/j.jocn.2020.04.062Search in Google Scholar PubMed PubMed Central

28. Poyiadji, N, Shahin, G, Noujaim, D, Stone, M, Patel, S, Griffith, B. COVID-19-associated acute hemorrhagic necrotizing encephalopathy: CT and MRI features. Radiology 2020:201187.10.1148/radiol.2020201187Search in Google Scholar PubMed PubMed Central

29. Markus, HS, Brainin, M. COVID-19 and stroke—a global World Stroke Organization perspective. Int J Stroke. 2020;15:361–4. https://doi.org/10.1177/1747493020923472.Search in Google Scholar

30. Oxley, TJ, Mocco, J, Majidi, S, Kellner, CP, Shoirah, H, Singh, IP, et al.. Large-vessel stroke as a presenting feature of Covid-19 in the young. N Engl J Med. 2020;382:e60. https://doi.org/10.1056/nejmc2009787.Search in Google Scholar

31. Szperka, CL, Ailani, J, Barmherzig, R, Klein, BC, Minen, MT, Halker Singh, RB, et al.. Migraine care in the era of COVID‐19: clinical pearls and plea to insurers. Headache J Head Face Pain. 2020;60:833–42. https://doi.org/10.1111/head.13810.Search in Google Scholar

32. Brann, D, Tsukahara, T, Weinreb, C, Logan, DW, Datta, SR. Non-neural expression of SARS-CoV-2 entry genes in the olfactory epithelium suggests mechanisms underlying anosmia in COVID-19 patients. BioRxiv 2020.10.1101/2020.03.25.009084Search in Google Scholar

33. Torabi, A, Mohammadbagheri, E, Akbari Dilmaghani, N, Bayat, AH, Fathi, M, Vakili, K, et al.. Proinflammatory cytokines in the olfactory mucosa result in COVID-19 induced anosmia. ACS Chem Neurosci 2020;11:1909–13.10.1021/acschemneuro.0c00249Search in Google Scholar PubMed PubMed Central

34. Gane, SB, Kelly, C, Hopkins, C. Isolated sudden onset anosmia in COVID-19 infection. A novel syndrome. Rhinology 2020;58:10.10.4193/Rhin20.114Search in Google Scholar PubMed

35. Jiang, F, Deng, L, Zhang, L, Cai, Y, Cheung, CW, Xia, Z. Review of the clinical characteristics of coronavirus disease 2019 (COVID-19). J Gen Intern Med 2020;35:1–5.10.1007/s11606-020-05762-wSearch in Google Scholar PubMed PubMed Central

36. Gao, J, Tian, Z, Yang, X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020;14:72–3.10.5582/bst.2020.01047Search in Google Scholar PubMed

37. Chen, C, Huang, J, Cheng, Z, Wu, J, Chen, S, Zhang, Y, et al.. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. MedRxiv 2020. https://doi.org/10.18632/aging.104092.Search in Google Scholar

38. Xu, X, Han, M, Li, T, Sun, W, Wang, D, Fu, B, Zhou, Y, Zheng, X, Yang, Y, Li, X, Zhang, X. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA 2020;117:10970–5. https://doi.org/10.1073/pnas.2005615117.Search in Google Scholar

39. Sahin, AR, Erdogan, A, Agaoglu, PM, Dineri, Y, Cakirci, AY, Senel, ME, et al.. 2019 novel coronavirus (COVID-19) outbreak: a review of the current literature. EJMO 2020;4:1–7.10.14744/ejmo.2020.12220Search in Google Scholar

40. Batlle, D, Wysocki, J, Satchell, K. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? Clin Sci 2020;134:543–5. https://doi.org/10.1042/cs20200163.Search in Google Scholar

Received: 2020-09-19

Accepted: 2021-02-06

Published Online: 2021-02-23

You are currently not able to access this content.

Articles in the same Issue

https://doi.org/10.1515/hmbci-2020-0069

Keywords for this article

COVID-19; neurology; neuropathology; SARS-CoV-2